Alfred Chung, Assistant Professor
Dr. Alfred Chung is a hematologist-oncologist who cares for patients with blood cancers, including leukemias, lymphomas and myelomas. He sees patients who are in the hospital for treatment, including those who need a bone marrow transplant and those receiving chemotherapy or cellular therapies to bolster the immune system.
Chung's research centers on the study and development of new therapies for plasma cell disorders, including multiple myeloma and amyloidosis (buildup of an abnormal protein called amyloid in the organs). One specific area of study is light chain amyloidosis, in which the dysfunction of certain antibody-producing cells results in abnormal protein fibers in the organs. Chung is looking specifically at targeted therapies to treat this type of amyloidosis as well as novel therapeutic strategies in the treatment of multiple myeloma.
After earning a bachelor's degree in chemical engineering at the University of Michigan, Chung earned a medical degree at Northwestern University Feinberg School of Medicine. At Stanford Medicine, he completed a residency in internal medicine, followed by a fellowship in hematology and oncology.
Chung is a member of the American Society of Clinical Oncology, American Society of Hematology and Association of Northern California Oncologists.
Financial relationships
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Bristol Myers SquibbTopic:Research FundingDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:TravelIneligible company:JanssenDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenTopic:Advisory BoardDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:JanssenTopic:Research FundingDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:AbbvieTopic:Research FundingDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:CarsgenTopic:Research FundingDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Caelum BiosciencesTopic:Research FundingDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:CellectisTopic:Research FundingDate added:02/27/2024Date updated:02/27/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:MerckTopic:Research FundingDate added:02/27/2024Date updated:02/27/2024